Investor Relations

1.  Bot Image’s first proprietary technology ProstatID TM has been developed in coordination with the NIH and UCLA. ProstatID was FDA cleared for marketing in July 2022.

​

2.  An attractive business model with low overhead and high returns. Our projected profit model only requires capturing .06% of the entire United States market.

​

3.  Industry leadership with an experienced management team and board of directors that have an excellent track record of bringing novel diagnostic imaging technologies to market cost-effectively with high financial returns.

 

4.  Robust industry-specific sales channels developed over two decades gives us a strong competitive position.

​

5.  Disciplined financial policies that focus on maintaining a strong and stable capital structure and cash flow growth.

​

6.  A clear road map for expansion, focused on executing an attractive portfolio of AI projects to adapt to emerging markets.

​

7.  Vertically-integrated business covering the entire downstream segment of the magnetic resonance industry with transparent group structure with defined business segments and product lines.

​

8.  Committed to optimizing our investments with full transparency to generate value and sustained growth.

​

9.  Maintains a high pace of innovation and owns a self-financed portfolio of new products with reported and controlled costs.

​

10.  Growth from multiple dimensions including the development of new technologies, leveraging current platforms to develop new products and applications, and geographical expansion capabilities.

​

11.  Technologies and products that reduce the cost of medical care, improve diagnostic accuracy, and save lives.

​

12.  Attractive market with immense projected growth profile, the AI market is forecasted to hit $15.7 billion and healthcare to hit $14.8 trillion by 2030.